School of Medicine


Showing 681-700 of 1,182 Results

  • Ryan Matlow

    Ryan Matlow

    Clinical Associate Professor, Psychiatry and Behavioral Sciences

    BioRyan Matlow, Ph.D., is a child clinical psychologist who serves as Director of Community Programs for Stanford’s Early Life Stress and Resilience Program, and is a faculty member in Stanford's Human Rights and Trauma Mental Health Program. His clinical and research efforts focus on understanding and addressing the impact of stress, adversity, and trauma in children, families, and communities. In particular, Dr. Matlow seeks to apply current scientific knowledge of the neurobiological and developmental impact of stress, trauma, and adversity in shaping interventions and systems of care. Dr. Matlow is focused on engaging diverse populations and providing evidence-based individual, family, and systems interventions for posttraumatic stress following interpersonal trauma, with an emphasis on efforts in school, community, and integrated care settings. He is engaged in clinical service, program development, and interdisciplinary collaboration efforts that address childhood trauma exposure in communities that have been historically marginalized, under-resourced, and/or experienced human rights violations. He has worked extensively in providing trauma-focused psychological evaluation, treatment, and advocacy services with immigrant youth and families, with a focus on immigrants from Latin American countries. Dr. Matlow is involved in the training and dissemination of Stanford's Cue Centered Therapy (Carrion, 2015), a flexible, manualized intervention addressing childhood experiences of chronic trauma.

  • LAWRENCE McGLYNN

    LAWRENCE McGLYNN

    Clinical Professor, Psychiatry and Behavioral Sciences - Medical Psychiatry

    Current Research and Scholarly InterestsMethamphetamine Abuse
    HIV Neuropsychiatry

  • Mark McGovern

    Mark McGovern

    Professor of Psychiatry and Behavioral Sciences (Public Mental Health and Population Sciences)

    BioDr. Mark McGovern is a Professor in the Department of Psychiatry & Behavioral Sciences and, by courtesy, the Department of Medicine at Stanford University School of Medicine.

    Most people who need health care do not receive it. And of those who do, wide variation exists in the quality of the care they receive. Gaps in health care access and quality are worse for certain groups, such as underrepresented minorities and persons living in low-resourced urban and rural areas, and/or in poverty. Enormous disparities exist in health care systems, both private and public. Dr. McGovern is a leader in using rigorous methods of dissemination and implementation (D&I) science to close these gaps in equitable health care delivery.

    His mission is to get the best health care possible to the people who need it the most.

    Dr. McGovern's primary focus is the implementation and sustainment of evidence-based interventions and guideline adherent care in public and private health care systems and organizations. Within the hub of the Center for Dissemination and Implementation (CDI) which he directs, Dr. McGovern is the Principal Investigator (PI) and leads three national dissemination and implementation (D&I) centers: The Center for Dissemination and Implementation At Stanford (C-DIAS); The Research Adoption Support Center (RASC); and, the Mental Health Technology Transfer Center Network Coordinating Center (MHTTC). The 3 centers are federally-funded, respectively by the National Institute on Drug Abuse (P50DA05402), the National Institutes of Health Healing Addiction Long Term (HEAL) initiative (U2CDA057717), and the US Department of Health and Human Services Substance Use and Mental Health Services Administration (H79SM081726). Dr. McGovern is also the PI on a multi-site adaptive implementation trial across a state system of care, which aims to integrate addiction medications for persons with opioid use disorder who are receiving services in specialty or primary care organizations (R01DA052975). In addition, he conducts D&I research and practice projects in federally-qualified health centers (FQHCs) across the State of California, in the Stanford Division of Primary Care and Population Health, and in specialty addiction and mental health treatment organizations nationwide. He leads, facilitates and/or actively engages networks advancing D&I science in health, including the NIDA Clinical Trials Network Translation & Implementation Special Interest Group, the NIDA Clinical Trials Western States Node Translation & Implementation Workgroup, the Stanford University Network for Dissemination & Implementation Research (SUNDIR), the VA Palo Alto HSR&D Center for Innovation to Implementation, and the Stanford Medicine Center for Improvement. He is on the Core Faculty of the National Institute of Mental Health Implementation Research Institute at the Washington University in St. Louis. Dr. McGovern is a collaborator on multiple projects as a co-investigator, consultant, or advisory board member. He is a mentor to numerous individuals across the country and at Stanford, from university undergraduates to mid-career faculty and clinical administrators at academic institutions and health care systems nationwide.

  • Carmen McLean

    Carmen McLean

    Clinical Professor (Affiliated), Psych/General Psychiatry and Psychology (Adult)

    BioCarmen McLean, PhD, is a clinical psychologist and researcher with the Dissemination and Training Division of the National Center for PTSD at the Palo Alto VA Health Care System. Dr. McLean’s research focuses on increasing the implementation and reach of evidence-based treatments for posttraumatic stress disorder (PTSD).

  • M Windy McNerney, PhD

    M Windy McNerney, PhD

    Clinical Associate Professor (Affiliated), Psych/General Psychiatry and Psychology (Adult)
    Staff, Psychiatry and Behavioral Sciences

    BioDr. M. Windy McNerney is the Director of Biological Sciences for the MIRECC at the Department of Veterans Affairs in Palo Alto, and a Clinical Associate Professor (Affiliated) at Psychiatry and Behavioral Sciences at Stanford School of Medicine. Dr. McNerney holds a particular passion for not only understanding the neurophysiology and biochemistry of mental health diseases, but also advocating for these invisible diseases. Her research focuses on neurodegeneration, depression, TBI, PTSD, and addiction. She is collaborating with researchers to integrate brain imaging and biochemical markers in hopes to better understand these diseases. She also is taking a lead role at the VA in investigating the biochemistry of magnetic brain stimulation and is the leader of the NeuroNado Laboratory. At Stanford University, she is the professor of two popular courses examining the biological and societal issues surrounding substance use disorder, with a major focus on opioids such as fentanyl. She has individually mentored over 25 students from underrepresented groups in STEM activities and leads monthly seminars aimed at facilitating career development. In her free time, she is a community advocate for the treatment of mental health and educates groups about the dangers of fentanyl.

    She earned her BS from UC Davis and her PhD from the University of Notre Dame. While at ND, she interned at NASA Ames on Human Factors Engineering. She then went on to a postdoctoral position at Lawrence Livermore National Laboratory (DOE), and then completed a fellowship at the WRIISC program at the VA and Stanford University.


    Selected Publications:

    McNerney MW, Gurkoff G, Berryhill M (2023). The rehabilitation potential of neurostimulation for mild traumatic brain injury in animal and human studies. Brain Sciences, 13, 1402.

    McNerney MW, Kraybill EP Narayanan S, Mojabi F, Venkataramanan V, Heath A (2023). Memory-related hippocampal brain-derived neurotrophic factor activation pathways from repetitive transcranial magnetic stimulation in the 3xTg-AD mouse line. Experimental Gerontology, 183, 11323.

    Shuken, S, McNerney MW (2023). Cost and benefits for popular p-value correction methods I three models of quantitative omic experiments. Analytical Chemistry, 95, 2732.

    McNerney MW, Heath A, Narayanan S, Yesavage J (2022). Repetitive transcranial magnetic stimulation improves brain-derived neurotrophic factor and cholinergic signaling in the 3xTgAD mouse model of Alzheimer’s disease. Journal of Alzheimer’s Disease, 86, 499..

    Heath AM, Brewer M, Yesavage J, McNerney MW. (2021). Improved object recognition memory using post-encoding repetitive transcranial magnetic stimulation. Brain Stimulation, 15, 78.

    Yang AC, Vest RT, Kern F, Lee DP, Agam M, Maat CA, Losada PM, Chen MB, Schaum N, Khoury N, Toland A, Calcuttawala K, Shin H, Palovics R, Shin A, Wang EY, Luo J, Gate D, Schultz-Schaeffer WJ, Chu P, Siegenthalar J, McNerney MW, Keller A, Wyss-Coray T (2022). A human brain vascular atlas reveals diverse mediators or Alzheimer’s disease. Nature, 603, 885.

    McNerney MW, Hobday T, Cole B, Ganong R, Winas N, Matthews D, Hood J, Lane S (2019). Objective classification of mTBI using machine learning on a combination of frontal electroencephalography measurements and self-reported symptoms. Sports Medicine Open, 4, 14.

    McNerney MW, Sheng T, Nechvatal JM, Lee A, Lyons D, Adamson M (2018). Integration of neural and epigenetic contributions to posttraumatic stress symptoms: The role of hippocampal volume and glucocorticoid receptor gene methylation. PLOSONE, e0192222.

    Bennion BJ, Be NA, McNerney MW, Lao V, Carlson E, Valdez CA (2017). Predicting a drug’s membrane permeability: A computational model validated with in vitro permeability assay data. Journal of Physical Chemistry, B, 121, 5228.

    See more publications at: https://www.ncbi.nlm.nih.gov/pubmed/?term=McNerney%20MW%5BAuthor%5D&cauthor=true&cauthor_uid=17107728